19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
20:30 , Oct 29, 2018 |  BC Extra  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million. The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund III...
17:54 , Jul 13, 2018 |  BioCentury  |  Finance

Forbion builds immunity

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in...
07:01 , Jul 11, 2018 |  BC Extra  |  Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million ($294.2 million). The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital...
23:13 , Apr 18, 2017 |  BC Extra  |  Company News

Novartis, Allergan planning NASH combo trial

Novartis AG (NYSE:NVS; SIX:NOVN) and Allergan plc (NYSE:AGN) said they will test a combination including a farnesoid X receptor (FXR; NR1H4) agonist from Novartis and cenicriviroc (formerly TBR-652) from Allergan in a Phase IIb trial...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
07:00 , Oct 3, 2016 |  BioCentury  |  Strategy

Combo deals

Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology. Together, Allergan's Sept. 20 deals...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

Akarna, Allergan deal

Allergan acquired Akarna for $50 million up front and undisclosed development, regulatory and sales milestones tied to lead asset AKN-083 , a farnesoid X receptor (FXR; NR1H4 ) agonist that is in preclinical development to...
07:00 , Sep 20, 2016 |  BC Extra  |  Top Story

Allergan acquiring NASH companies Tobira, Akarna

Allergan plc (NYSE:AGN) said Tuesday it had acquired a pair of companies with "complementary" assets to treat non-alcoholic steatohepatitis. Before market hours, it said it would buy Tobira Therapeutics Inc. (NASDAQ:TBRA). After market close, it...